A Stefani-Alessandro

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 171 publications

Efficacy of citicoline as an add-on therapy in Parkinson's disease: a randomized, double-blind trial.

Efficacy of citicoline as an add-on therapy in Parkinson's disease: a randomized, double-blind trial.

Journal: Parkinsonism & related disorders

Published: April 27, 2026

Alzheimer's Disease Cerebrospinal Fluid Biomarkers Predict Survival in Progressive Supranuclear Palsy.

Alzheimer's Disease Cerebrospinal Fluid Biomarkers Predict Survival in Progressive Supranuclear Palsy.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: March 19, 2026

Frequency- and Network-Specific Changes in Functional Connectivity Reflect Pathophysiological Mechanisms across Parkinson's Disease Stages.

Frequency- and Network-Specific Changes in Functional Connectivity Reflect Pathophysiological Mechanisms across Parkinson's Disease Stages.

Journal: Annals of neurology

Published: March 09, 2026

Effect of continuous subcutaneous foslevodopa/foscarbidopa infusion on gait in advanced Parkinson's disease: a real-world wearable-based study.

Effect of continuous subcutaneous foslevodopa/foscarbidopa infusion on gait in advanced Parkinson's disease: a real-world wearable-based study.

Journal: Journal of neurology

Published: January 26, 2026

Clinical, Biological, and Functional Connectivity Profile of Patients With De Novo Parkinson Disease Who Are APOE ε4 Carriers.

Clinical, Biological, and Functional Connectivity Profile of Patients With De Novo Parkinson Disease Who Are APOE ε4 Carriers.

Journal: Neurology

Published: December 05, 2025

Unveiling the Role of Sex Hormones and Reproductive Life Factors in Parkinson's Disease.

Unveiling the Role of Sex Hormones and Reproductive Life Factors in Parkinson's Disease.

Journal: Movement disorders clinical practice

Published: November 06, 2025

Foslevodopa/Foscarbidopa Overnight Administration Improves Nocturia in Patients with Parkinson's Disease: Evidence from a Real-World Study.

Foslevodopa/Foscarbidopa Overnight Administration Improves Nocturia in Patients with Parkinson's Disease: Evidence from a Real-World Study.

Journal: Movement disorders clinical practice

Published: November 05, 2025

SGK1 downregulation co-occurs with leukocyte oligomeric α-synuclein accumulation in Parkinson's disease.

SGK1 downregulation co-occurs with leukocyte oligomeric α-synuclein accumulation in Parkinson's disease.

Journal: Parkinsonism & related disorders

Published: October 13, 2025

Functional brain connectivity in patients with de novo Parkinson's disease.

Functional brain connectivity in patients with de novo Parkinson's disease.

Journal: Neuroimage. Reports

Published: September 24, 2025

Obstructive sleep apnea, periodic limb movements, and REM sleep without atonia are common in Parkinson's disease and correlate with motor symptom burden.

Obstructive sleep apnea, periodic limb movements, and REM sleep without atonia are common in Parkinson's disease and correlate with motor symptom burden.

Journal: Journal of Parkinson's disease

Published: September 22, 2025

Short-interval intracortical inhibition is related to high-frequency cortico-cortical functional connectivity in the human brain.

Short-interval intracortical inhibition is related to high-frequency cortico-cortical functional connectivity in the human brain.

Journal: Cerebral cortex (New York, N.Y. : 1991)

Published: September 16, 2025

Cell Cycle Dysfunction and Metabolic Alterations Consistent With Pathological Tau in Progressive Supranuclear Palsy Derived Fibroblasts.

Cell Cycle Dysfunction and Metabolic Alterations Consistent With Pathological Tau in Progressive Supranuclear Palsy Derived Fibroblasts.

Journal: Molecular neurobiology

Published: August 06, 2025

Showing 1-12 of 171

Last Updated: 09/26/2026